Stop Smoking Now!

Iomai Corporation (Nasdaq: IOMI) today announced grades from a 400-patient, Phase 2 dose-ranging tribulation of its patch-based vaccine all for travelers’ diarrhea. The trial be conduct to match up to the knack of a compass of vaccine dose to generate an immune rejoinder opposed to enterotoxigenic E. coli (ETEC) germs — the chief customary motivation of travelers’ diarrhea. Researchers found that even at the lowest dose tested, an Iomai patch applied to the arm generate a robust response within greater than 95 percent of patients.

The results be presented today by the use of Iomai’s Vice President of Clinical Development, Sarah A. Frech, DVM, at the Vaccines for Enteric Diseases 2007 agree in Lisbon, Portugal.

Teflon and the chemicals used in its harvest soak up grown into a $2 billion-a-year industry. This enmesh ammonium perfluorooctanoate, certain as C-8, which has been allied to cancer, organ blight and other strength effects in test on laboratory animals.

The terms will oblige us learn the dose that we will occupy in our ETEC article of export,” said Gregory M. Glenn, MD, Senior Vice President and Chief Scientific Officer of Iomai. “Iomai’s research wallow in shown that, added to to showing upcoming benefits against ETEC, the involved piece in the patch also works by means of an immune-boosting adjuvant when the patch is previously related in jumble beside inject vaccines for bug. Thus, the results from the dose-ranging ETEC enquiry will also help determine doses for at hand study of the Iomai booster patch for seasonal and pandemic influenza.” Travelers’ diarrhea perturb your abdomen linking 20 and 50 percent of global travelers to occupation where on floor the bacteria is endemic, but no ETEC vaccine is untaken in the United States. The ongoing strategy for avoid travelers’ diarrhea — prophylactic antibiotics — raise consideration about antibiotic conflict and linctus players effects.

The dose-ranging trial was designed to index level of an antibody, IgG, i.e. associated with guard against enterotoxigenic E. coli. Four dissimilar doses — 7.5 micrograms, 22.5 micrograms, 37.5 micrograms and 50 micrograms — and a placebo patch were tested, and antibody levels were checked at 21 and 42 days. The results lay bare that nearly all patients in the four dose mass respond to the vaccine, with even the lowest dose of the vaccine evoke a response in more than 95 percent of patients.

Both EMEA in Europe and the FDA in the US have careworn the complication of finding out if the symptoms are in the red to varenicline. People can become depressed when they stop smoking, whether they take a drug to help them or not.

ABOUT IOMAI CORPORATION Iomai Corporation unearth and cultivate vaccines and immune regulations stimulants, deliver via a innovative, needle-free technology phone transcutaneous jab (TCI). TCI tap into the incomparable benefits of a crucial group of antigen-presenting cell found in the outer layer of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop untried vaccines that be viable simply through transcutaneous regime and extend the worldwide vaccine open market. Iomai presently has five product candidate in beginning: four target influenza and pandemic infection and one to rule out E. coli-related travelers’ diarrhea. For more facts by the side of Iomai, humour call rounded Some matter bad blood here tighten liberty constitute “forward-looking statements” that snare planned and unknown stake and uncertainties that could cause actual results to be different materially from those expressed or implied by the forward-looking pronouncement. Such forward-looking statements meditate on statements about the ability of Iomai’s travelers’ diarrhea patch vaccine to stimulate robust immune response, the use of these results to determine doses for future studies of Iomai’s vaccine candidates for travelers’ diarrhea and pandemic and seasonal influenza. Applicable risks and uncertainties include, among others, that results in the trial describe in this press release may not give the needed information obligatory to conduct future trial, that Iomai may not be practised of enroll an celebration amount of numbers of patients in future clinical trials; that future clinical trials may not model results see in the trials described in this press release; that Iomai may be incompetent to receive a purchase of the regulatory approvals necessary to conduct further clinical trials or to market any product candidates for travelers’ diarrhea, pandemic and seasonal influenza; that development costs may outdistance expectations; that Iomai may backfire to agreeably look after its marginal lavishness or may be plucky to contravention on the intellectual property of others; and the risks identified beneath the heading “Risk Factors” in its Annual Report on Form 10-K for the year terminated December 31, 2006 and file with the Securities and Exchange Commission. Iomai caution saver and others not to set undue hope on the forward-looking statements contained in this press release. You are short of to read the Company’s filings for a discussion of these and other risks and uncertainties which are filed with the U.S. Securities and Exchange Commission, available at Iomai Corporation

Press to learn here more generic cialis pills